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Precision medicine with molecularly directed therapeutics is rapidly expanding in all 
subspecialties of oncology. Molecular analysis and treatment monitoring require tumor 
tissue, but resections or biopsies are not always feasible due to tumor location, patient 
safety, and cost. Circulating tumor cells (CTCs) offer a safe, low-cost, and repeatable 
tissue source as an alternative to invasive biopsies. “Liquid biopsies” can be collected 
from a peripheral blood draw and analyzed to isolate, enumerate, and molecularly char-
acterize CTCs. While there is deserved excitement surrounding new CTC technologies, 
studies are ongoing to determine whether these cells can provide reliable and accurate 
information about molecular drivers of cancer progression and inform treatment deci-
sions. This review focuses on the current status of CTCs in genitourinary (GU) cancer. 
We will review currently used methodologies to isolate and detect CTCs, their use as 
predictive biomarkers, and highlight emerging research and applications of CTC analysis 
in GU malignancies.
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iNTRODUCTiON
Circulating tumor cells (CTCs) are cancer cells that are shed from a primary or metastatic tumor 
site, traffic through the vasculature, and may establish distant metastasis. CTCs were first reported as 
far back as the late 1800s: Ashworth detected the cells in blood drawn from the saphenous vein and 
postulated that they would be identical to the primary tumor (1). However, CTCs began to make a 
significant scientific and clinical impact on cancer only in the recent decade, enabled by technologi-
cal advancements that allow improved detection and isolation of these rare cells from blood.
Circulating tumor cells have been identified and isolated from patients with virtually every type 
of solid malignancy. Cancers of the prostate, bladder, and kidney comprise 3 of 10 most common 
primary malignancies diagnosed in the United States (2), and CTCs have been isolated from each of 
these malignancies. While numerous studies have focused on CTCs in patients with prostate cancer, 
few studies have focused on other genitourinary (GU) malignancies including bladder, kidney, and 
testicular.
In this review, we will focus on CTCs with respect to their role in GU malignancies. We will first 
provide a brief synopsis highlighting some of the currently available technologies used to identify 
and recover CTCs. We will then review how CTCs are being developed clinically as prognostic and 
predictive biomarkers in GU malignancies. Finally, we will address how CTCs are being leveraged to 
elucidate disease biology by identifying key mechanisms of resistance and progression.
FiGURe 1 | Circulating tumor cell (CTC) identification and isolation. CTC workflows: immunoaffinity generally utilizes antibody to epithelial cell adhesion 
molecule and is dependent on EPCAM+ CTCs. Size-based filters are reliant on typically larger size of CTCs. All techniques require some form of staining for cellular 
identification. Common stains include cytokeratin, 4′,6-diamidino-2-phenylindole (DAPI), leukocyte common antigen (CD45), and others. DEPArray™ enables 
isolation of individual, intact cells in dielectric cages. Apostream® allows for antibody-independent capture of CTCs. Epic Sciences™ places unenriched sample on 
proprietary slide prior to CTC staining and high-resolution scanning. Downstream analysis opportunities are numerous and continue to be explored.
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BRieF SYNOPSiS OF TeCHNOLOGieS
Several different methods have been developed to isolate and 
analyze CTCs. Each detection strategy exploits a different physi-
cal property of the cells in order to separate them from the billions 
of red blood cells and millions of white blood cells (WBC) also 
present in a standard 7.5  ml sample of human blood (method 
overview in Figure 1).
The most clinically established method to isolate CTCs is 
immunoaffinity (3). This method employs magnetic beads 
attached to antibodies directed at specific cell surface antigens 
present on CTCs, most commonly epithelial cell adhesion 
molecule (EpCAM). After the antibodies bind to their target, 
a magnet is used to separate these cells from background cells. 
The most heavily studied immunoaffinity device has been the 
CellSearch® platform (developed by Janssen Diagnostics, LLC 
and recently acquired by Menarini-Silicon Biosytems). This FDA-
cleared system uses ferrofluid nanoparticles attached to antibod-
ies directed against EpCAM on CTCs to separate these cells from 
other cells present in the buffy coat following centrifugation of 
whole blood. Once separated, these cells are then stained with 
fluorophore-labeled antibodies directed against cytokeratin (CK), 
CD45 (a leukocyte-specific cell marker), and the 4′,6-diamidino-
2-phenylindole (DAPI) nuclear stain. Cells that stain EpCAM+, 
CK+, CD45−, with DAPI+ are considered CTCs (4).
Another example of a system-utilizing immunoaffinity is the 
CTC-chip platform. The CTC-chip has thousands of small posts 
embedded with EpCAM antibodies. Blood flows through the chip 
and cells expressing EpCAM on their surface bind to the posts 
and are separated from non-EpCAM expressing cells (5, 6). The 
CTC-iChip uses immunoaffinity combined with microfluidics to 
isolate CTCs but does not rely on EpCAM labeling. This device is 
composed of two chips that first separate nucleated cells present 
in whole blood from non-nucleated cells using deterministic lat-
eral displacement which separates cells via size-based deflection. 
The WBCs are also tagged with CD45 and CD66b (a more specific 
target of granulocytes) antibodies during this phase. The second 
step uses inertial focusing and magnetophoresis to separate the 
remaining nucleated cells based on their magnetic bead load, 
which separates CTCs from WBCs (7).
Immunoaffinity-based techniques have advantages as well 
as limitations: the most notable strength of these approaches 
is their extensive validation to date. CellSearch has by far been 
the most commonly used method in large clinical trials across 
malignancies, where it has been validated repeatedly and 
become a de facto “gold standard” to which emerging technolo-
gies are compared. If a tumor-specific cell surface marker is 
available for a given malignancy, immunoaffinity can serve as 
a sensitive and specific strategy for enriching cancer cells from 
the blood. Conversely, the main limitation of immunoaffinity-
based techniques is that such a sensitive and specific marker 
often is not available. EpCAM-based systems may fail to 
identify subsets of cells undergoing epithelial-to-mesenchymal 
transition (EMT). This phenotypic transformation is thought 
to be necessary for cells to migrate from the primary tumor 
location and metastasize. These cells often downregulate 
EpCAM antigen and express mesenchymal antigens instead, 
thus reducing the sensitivity of an EpCAM-based approach. 
Moreover, EpCAM is not a CTC-specific marker per  se, but 
rather a marker of all epithelial cells; thus, it is possible that 
some CTCs enriched in this manner may not be tumor cells 
but rather benign epithelial cells, thus reducing the specificity 
of EpCAM-based enrichment.
A second broad methodology used to isolate CTCs is based 
on size and deformability, as CTCs are typically larger and more 
rigid than WBCs. Many groups have described variations of this 
technique, and some examples include use of a Parylene-C slot 
microfilter (8), a porous polycarbonate membrane (9), a reset-
table trap with adjustable aperture (10), and a polycarbonate 
track-etch-type membrane with cylindrical pores (11).




97 patients with localized prostate cancer evaluated for CTCs prior to planned prostatectomy as well as various intervals following surgery. CTCs 
detected in 21% of patients and did not correlate with tumar volume, pathological stage, or Gleason score
Pal  
et al. (19)
Sample blood from 35 patients with high-risk localized prostate cancer collected prior to treatment. CTCs identified in 49% prior to surgery but no 
correlation between CTC count and biochemical recurrence identified at 1 year follow-up
Metastatic hormone-sensitive prostate cancer (mHSPC)
Okegawa  
et al. (21)
SO patients identified prior to initiation of hormonal therapy. CTC counts ranged from 0 to 222/7.5 ml blood, with 44 patients having 5 or more CTCs. 
More than 5 CTCs median androgen deprivation therapy (ADT) responsiveness 17 months vs 32 for those with <5CTCs
Goldkorn  
et al. (35)
CTCs detectable in 78/211 (37%) patients in CTC enumeration corollary to SWOG 1216 (ADT plus bicalutamide or orteronel in setting of MHSPC). 
Baseline CTC detection associated with higher prostate-specific antigen (PSA), extensive disease, and bony metastasis. Trial ongoing including 
molecular characterization
Metastatic castrate-resistant prostate cancer (mCRPC)
de Bono  
et al. (24)
Evaluation of 231 patients prior to initiating new line chemotherapy and monthly thereafter. Patients stratified to favorable (<5) vs unfavorable (>5) CTC 
counts. CTC count superior to PSA for predicting OS (11.5 vs 21.7 months) among those with unfavorable CTC count
Scher  
et al. (25)
147 eligible patients from IMMC38 trial identified prior to initiation of chemotherapy. Changes in CTC number strongly associated with risk of death at 4, 
8, and 12 weeks after treatment suggesting CTC number as a continuous variable useful for disease status monitoring
Goldkorn  
et al. (29, 30)
Prognostic value of CTCs for overall survival and disease response assessed in SWOG 0421(docetaxel plus prednisone with or without atrasentan). 
Baseline CTC counts found to be prognostic of overall survival and rising CTCs at 3 weeks predicted worse OS. In addition, telomerase activity in CTCs 
captured on Parylene-C microfilter found prognostic of overall survival (19 vs 12 months) in men with 6–54 CTCs/7.5 ml
Antonarakis  
et al. (39)
RT-PCR identified androgen receptor splice variant 7 (AR-V7) splice variant in CTCs of patients receiving enzalutamide or abiraterone for mCRPC. AR-V7 
in CTCs associated with lower PSA response, shorter PFS, and decreased OS
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Size-based techniques offer several pros and cons: one 
advantage compared with immunoaffinity-based technologies is 
that cell isolation does not rely on cell surface markers, allowing 
for the capture of cells that do not express the platform-specific 
antigen. Another advantage, compared with CellSearch®, is 
that cells do not require fixation and therefore live cells can be 
captured and further manipulated. On the other hand, size-based 
platforms have limited sensitivity and specificity, because they 
may retain large cells that are not CTCs or fail to capture smaller 
CTCs. Additionally, once these cells are captured, they require 
additional positive identification steps (e.g., immunofluorescent 
staining) (3).
Several other methodologies exist to capture and identify 
CTCs based on a variety of cellular features. Examples include 
the DEPArray™ (Silicon Biosystems, Italy) system, which uses a 
microfluidic cartridge with controllable electrodes to create die-
lectric cages around cells for isolation and recovery (12). Another 
dielectric separation-based system is ApoStream® (Apocell Inc., 
Houston, TX, USA), which also exploits the differences in dielec-
tric properties between CTCs and peripheral blood mononuclear 
cells to focus and separate cells (13). Others have isolated CTCs 
based on their ability to invade collagenous matrices, or using 
atomic force microscopy to determine the nanomechanical 
properties of CTCs such as elasticity, deformation, and adhesion 
to identify CTCs (14, 15). All of these approaches offer unique 
advantages and disadvantages based on sensitivity, specificity, 
speed, and reproducibility of workflow, and compatibility with 
fixed vs live cells. In-depth discussion of each is beyond the scope 
of this review.
More recently, two platforms have eschewed enrichment alto-
gether and instead take a “no cell left behind” approach using rapid 
high-resolution scanning and automated detection algorithms 
to identify CTCs. Epic™ (Epic Sciences, San Diego, CA, USA) 
utilizes immunofluorescent staining (CK, DAPI, CD45, as well 
as one or two additional antibodies) of nucleated cells spread as 
a monolayer on proprietary slides. These slides are then scanned 
using a whole slide fluorescent microscope. A computerized algo-
rithm then incorporates immunofluorescent and morphologic 
features to identify candidate CTCs (16). Rarecyte™ (RareCyte, 
Seattle, WA, USA) spreads the buffy coat on slides and then per-
forms automated multiplex imaging with scanning algorithms to 
detect and rank potential CTCs (17). Advantages of these systems 
include rapid detection, automation, and the ability to map and 
characterize the entire complement of circulating cells, regardless 
of size or antigen expression. However, the cells are fixed to a 
solid matrix that somewhat limits manipulation, precludes live 




The majority of CTC research and clinical development to date in 
GU malignancies has been undertaken in patients with prostate 
cancer, and most of these studies have used CTC enumeration 
as their clinical end point. Beyond enumeration, recent studies 
have begun to molecularly characterize isolated CTCs and to 
study their nanomechanical properties as enabling downstream 
technologies continue to develop. Prostate cancer CTC enu-
meration studies have been performed in the full spectrum of 
disease states, from localized prostate cancer (18, 19), to meta-
static hormone-sensitive prostate cancer (mHSPC) (20–22), to 
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metastatic castrate-resistant prostate cancer (mCRPC) (23–28). 
In the following sections, we will review studies in each of these 
areas (selected prospective studies highlighted in Table 1).
Castrate-Resistant Prostate Cancer
Therapeutic options for mCRPC have expanded markedly 
over the past decade and now include several new hormonal 
therapies, chemotherapies, a vaccine, and a radiopharma-
ceutical. Informative new biomarkers may help guide choice 
of therapy. In one of the first published studies, Danila et  al. 
(25) enumerated CTCs from 120 patients with mCRPC using 
the CellSearch® platform and showed that CTC enumeration, 
when treated as a continuous variable, was inversely associated 
with overall survival. The combination of CTC enumeration, 
prostate-specific antigen (PSA), and albumin was found to be 
a better predictor of survival than any of these individual vari-
ables alone. CTC counts were higher in patients with bone vs 
soft-tissue metastasis and in those who received prior cytotoxic 
chemotherapy.
In a seminal mCRPC study by de Bono et al. (24), CellSearch® 
was used to enumerate CTCs in 276 patients with metastatic 
CRPC treated with various hormonal agents and chemotherapies. 
CTCs were detected in 231 patients, and patients with ≥5 CTCs 
had significantly worse overall survival than patients with <5 
CTCs (11.5 vs 21.7 months, HR 3.3, p < 0.0001). This CTC cutoff 
value was also a better predictor of overall survival than PSA at 
1 year. Interestingly, patients whose CTCs increased from <5 at 
baseline to ≥5 at subsequent time points had worse outcomes, 
whereas patients who converted from ≥5 to <5 CTCs had better 
outcomes than patients who remained stable. Goldkorn et  al. 
(29) confirmed this CTC cut point in a prospective randomized 
phase III study, SWOG 0421. Patients with mCRPC were treated 
with docetaxel ± atrasentan, and those with baseline CTC counts 
of ≥5 vs <5 had median overall survival differences of 13 vs 
26 months, respectively (HR, 2.74, 95% CI, 1.72–4.37, p < 0.001). 
Moreover, any increase in the CTC count after cycle 1 of therapy 
(at 3 weeks from baseline) was associated with reduced overall 
survival (HR, 2.55, 95% CI, 1.04–6.24, p = 0.041). In a parallel 
study, Goldkorn et al. (30) evaluated telomerase activity in CTCs 
isolated from patients enrolled in SWOG 0421 and found that 
this cancer marker predicted overall survival in patients with 
CTC counts ≥5. While de Bono and Goldkorn arrived at a cutoff 
of ≥5 or <5 CTCs, Goodman et  al. (23) performed threshold 
analysis from 100 patients with mCRPC and found that a CTC 
count of 4 was the optimal cutoff that best correlated with overall 
survival.
In a reanalysis of the 231-patient IMMC38 cohort described 
earlier (24), Scher et al. (26) found that dynamic CTC enumera-
tion monitoring at predefined “landmark” time points could be 
used to monitor disease status. CTC counts of ≥5 vs <5 at 4, 8, 
and 12 weeks following initiation of chemotherapy were associ-
ated with risk of death from prostate cancer, and CTC counts 
analyzed as a continuous variable (rather than specific cut points) 
also correlated with outcome.
A separate study by the same group (31) specifically evalu-
ated CTC enumeration as a surrogate for overall survival. This 
was a secondary objective of COU-AA-301, a multinational, 
randomized double-blind phase III trial of abiraterone acetate 
plus prednisone vs prednisone alone in patients with metastatic 
CRPC who were previously treated with docetaxel. CTC enu-
meration combined with lactate dehydrogenase values met the 
Prentice criteria for surrogacy in a predictive marker. Such fully 
validated surrogate biomarkers have the potential to shorten drug 
development times and potentially guide treatment choices, thus 
minimizing morbidity from non-efficacious treatment at an ear-
lier time point and maximizing the potential therapeutic efficacy 
from another agent.
Hormone-Sensitive Prostate Cancer
Circulating tumor cell analysis may prove useful in mHSPC as 
well, especially given recent studies demonstrating the benefit 
of combining hormonal therapy with chemotherapy (32, 33). Yu 
et al. (34) performed a corollary study as part of SWOG S0925, a 
randomized phase II trial of androgen deprivation therapy (ADT) 
combined with the IGF1 antibody cixutumumab vs ADT alone 
in patients with metastatic HSPC. They showed that baseline 
CTC enumeration categories of 0, 1–4, and ≥5 for 39 evaluable 
patients was associated with PSA categories of ≤0.2, >0.2 to ≤4.0, 
and >4.0 at 28 weeks, p = 0.036. Of note, 16 (41%) patients had 
undetectable CTC values at baseline. Goodman et al. (20) evalu-
ated multiple clinical variables including CTC enumeration in 33 
patients with mHSPC and demonstrated that only baseline CTC 
count was independently prognostic of progression to mCRPC. 
They found that ≥3 vs <3 was the optimal enumeration cutoff and 
this predicted a shortened time to mCRPC.
Another study (21) demonstrated that a baseline cutoff of 5 
CTCs in a cohort of 80 patients with mHSPC was an independent 
predictor of duration of ADT responsiveness (17 vs 32 months, 
p = 0.007). Furthermore, baseline PSA value was not a predictor of 
responsiveness; however, nadir PSA was a predictor. Additionally, 
a change in CTC count while on ADT was associated with treat-
ment response duration: response-free rates for patients with CTC 
counts ≥5 vs <5 at all time points was 32 vs 12 months (p < 0.001) 
and for patients with ≥5 baseline CTC count who decreased to <5 
during treatment it was 26 vs 12 months (p = 0.038). These results 
suggest that with additional validation, dynamic monitoring of 
CTC counts in HSPC may potentially be used as a clinical end 
point to guide changes in treatment strategy at an earlier point, 
possibly with improved outcomes.
Preliminary results of CTC studies in SWOG S1216, a 
randomized prospective phase III trial of MHSPC patients 
randomized to ADT in combination with either bicalutamide or 
orteronel, were recently presented at the 2016 American Society 
of Clinical Oncology meeting. Goldkorn et al. (35) demonstrated 
that CTCs were detectable in 78 of 211 (37%) of evaluable sam-
ples, and detection rates were impacted by whether patients were 
treatment naïve (41% detection) or had already initiated hormo-
nal therapy (29% detection) at time of baseline draw, p = 0.01. 
Additionally, baseline CTC detection was associated with higher 
PSA (p = 0.03), presence of extensive disease (p < 0.001), and 
bony metastasis (p = 0.05). Collectively, these enumeration stud-
ies are establishing an association between baseline CTC counts 
and other baseline prognostic factors, as well as with time to 
progression to mCRPC.
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Localized Disease
The majority of studies have focused on metastatic disease based 
on the expectation of finding more CTCs with greater disease bur-
den. However, several studies have evaluated CTCs in the context 
of localized prostate cancer with the goal of predicting recurrence 
after local definitive therapy. Pal et al. (19) collected blood from 
35 patients with high-risk localized prostate cancer and evaluated 
using CellSearch® to discover whether CTCs from this group 
expressed any mesenchymal cell markers that could indicate that 
these cells were undergoing EMT. Blood was collected 2 weeks 
prior to radical prostatectomy, at the time of surgery, and 1 and 
3 months following surgery and enriched CTCs were stained for 
the mesenchymal markers CD133 and E-cadherin. CTCs were 
detected in 49% of the 35 enrolled patients prior to surgery, and the 
percentages of CD133 and E-cadherin-positive CTC fragments 
were significantly higher in patients with biochemical recurrence 
at 1 year (p = 0.028 and 0.006, respectively). This detection rate is 
similar to the 52% detection rate noted by Kolostova et al. (9) in 
clinically localized prostate cancer.
Davis et al. (18) used CellSearch® preoperatively in 97 patients 
with clinically localized prostate cancer and detected CTCs in 
21% of patients. Interestingly, they also detected CTCs in 20% 
of the control group who had a negative extended-core prostate 
biopsy indicative of the inherent difficulties in CTC identifica-
tion, particularly when greater volumes of blood (30 ml in this 
study) are utilized increasing the potential inclusion of benign 
epithelial cells in the blood of healthy individuals. The authors 
suggest that CTCs might be used to determine which patients 
should undergo a repeat prostate biopsy following negative initial 
biopsy, an approach that warrants further investigation.
In the only systematic review and meta-analysis we identified 
in this field, Ma et al. (36) concluded that CTC counts are associ-
ated with overall survival and disease-free survival in patients 
with localized prostate cancer.
Molecular Characterization
As the sociologist William Bruce Cameron wrote: “not everything 
that can be counted counts, and not everything that counts can 
be counted”—CTC enumeration studies have provided a proof 
of concept for the detection and isolation of CTCs in humans, 
but the field is quickly moving beyond enumeration alone, with 
major efforts now focused on the molecular characterization of 
CTCs. Such studies aim to identify molecular drivers of treatment 
resistance or disease progression that can be used to monitor 
disease in real time and to direct personalized therapeutics.
Immunofluorescent Staining
As described earlier, the majority of CTC studies to date have 
employed immunofluorescence to some degree, whether simply 
to identify CTCs (EpCAM, CK, DAPI, CD45) or to characterize 
them (CD133, E-cadherin). Other examples include fluorescence 
in  situ hybridation (FISH) (37) to detect ERG rearrangements, 
PTEN loss, and AR copy numbers (38). Antonarakis et al. (39) 
investigated androgen receptor splice variant 7 (AR-V7) in CTCs. 
The Alere™ CTC AdnaTest (Alere Inc., San Diego, CA, USA) was 
used to enrich CTCs for real-time PCR detection of AR-V7 and 
full-length androgen receptor (AR). Presence of AR-V7 in CTCs 
was associated with resistance to abiraterone and enzalutamide. 
This work was confirmed and extended recently by Scher et al. 
who obtained blood samples from men with mCRPC undergoing 
a change in systemic therapy due to progressive disease and iden-
tified CTCs using the EPIC Sciences platform. AR-V7 presence 
detected by immunofluorescent staining was predictive of poor 
response to AR signaling inhibitors and improved response to 
taxane therapy, suggesting a potential role for CTC evaluation 
in directing advanced prostate cancer therapy (40). At least four 
separate groups have evaluated AR expression in CTCs. Miyamoto 
et al. (41) showed that patients with metastatic prostate cancer 
initiating ADT had significantly different AR staining patterns 
compared with metastatic CRPC patients initiating second-line 
therapies for CRPC. Reyes et al. used fluorescence-activated cell 
sorting (FACS) and ImageStreamX to produce real-time high-
resolution images of cells and demonstrated that AR expression 
was increased in patients with prior exposure to abiraterone and 
associated with increased Ki-67, a known cellular proliferation 
marker (42). On the other hand, Crespo et al. isolated CTCs using 
CellSearch® and then used FISH to demonstrate that AR expres-
sion in CTCs was unchanged in patients treated with enzalutamide 
or abiraterone, confirming these findings in tissue samples (43). 
Finally, Darshan et  al. demonstrated via immunofluorescence 
that AR localization in the CTC cytoplasm vs nucleus was associ-
ated with treatment response to chemotherapy (44). Therefore, 
monitoring CTC AR subcellular localization might be a useful 
clinical parameter for patients being treated with taxane based 
chemotherapy.
DNA/RNA Analysis
Increasingly, targeted and high-throughput methods are applied 
to amplified genetic material from rare cells captured from blood. 
Stott et al. (6) used CTC-chip followed by on-chip lysis to isolate 
RNA for RT-PCR evaluation of TMPRSS2-ERG translocation in 
metastatic patients to further the molecular characterization of 
prostate cancer CTCs. Punnoose et al. (45) used the Epic Sciences 
platform to identify CTCs and found that PTEN status in CTCs 
correlated with PTEN status in patient-matched CRPC tissue and 
that loss of PTEN in CTCs was associated with worse clinical out-
comes. Miyamoto et al. (46) used CTC-iChip to isolate 77 CTCs 
from patients with prostate cancer. These cells were microman-
ipulated, and the RNA content was extracted for amplification 
and next-generation sequencing. Considerable heterogeneity 
existed between individual CTCs with regard to expression of 
AR mutations and splicing variants—even between cells isolated 
from the same patient. Non-canonical Wnt5a was found to play 
an important role in overcoming the antiproliferative effect of AR 
inhibition. Jiang et al. (47) performed whole-genome sequencing 
on CTCs of patients with advanced prostate cancer by combining 
the NanoVelcro CTC-chip with laser capture microdissection to 
identify shared genomic alterations between CTCs and tumor 
tissues including structural variants in PTEN, RB1, and BRCA2. 
Similarly, Lohr et  al. (48) performed whole-exome sequencing 
on CTCs isolated from patients with metastatic prostate cancer 
as well as matched metastatic and primary tumor. 51/73 (70%) 
of CTC mutations were observed in matched tissue. In addition, 
90 and 73% of 10 early-trunk and 56 metastatic-trunk mutations, 
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respectively, found in the non-CTC tumor sample were also 
identified in CTC exomes.
An ongoing study embedded in a phase III prospective clini-
cal trial (SWOG 1216) employs multiparametric CTC profiling 
to illuminate mechanisms of androgen therapy resistance over 
time. CTCs are not only being enumerated but also enriched for 
targeted sequencing (Liquid Biopsy platform, Cynvenio) as well 
as recovered for gene expression analysis (DEPArray platform, 
Silicon Biosystems). Studies such as this will ultimately contribute 
to more informed and effective therapy selection in the mHSPC 
disease state.
CTC Culture
Expansion of CTCs in  vitro or in mouse avatar models holds 
potential for yielding large numbers of sustainable cells for 
molecular analysis and functional assays (e.g., drug sensitivity). 
This approach has met with some success in small cell lung cancer 
(49) and breast cancer (50). Unfortunately, experience has been 
more limited in prostate cancer, perhaps due to underlying differ-
ences in the biologies of these tumors, or due to lower abundance 
of recoverable CTCs. In one notable success, Gao et al. (51) were 
able to generate an organoid from CTCs isolated from a patient 
with metastatic prostate cancer. Whole-exome DNA sequencing 
demonstrated that this organoid expressed many of the same 
mutations present in archived formalin-fixed paraffin-embedded 
lymph node metastasis, but also with a few additional mutations. 
The authors suggest that these additional mutations may have 
been acquired during the transition from hormone-sensitive 
to castrate-resistant disease. Likewise, Vidal et  al. successfully 
established CTC-derived xenografts in order to examine the role 
of GATA2 in regulating prostate cancer progression and chemo-
therapy resistance. CD45-negative cells were isolated from the 
blood of CRPC patients after separation by Ficoll gradient using 
FACS and subsequently implanted into NSG mice demonstrating 
potential utilities of these techniques (52).
Another group used the MetaCell® system (MetaCell s.r.o., 
Ostrava, Czech Republic) to isolate viable intact CTCs. This sys-
tem uses a porous polycarbonate membrane to isolate cells based 
on size, successfully detecting CTCs at a high rate, 25/39 (64%) of 
patients with muscle-invasive bladder cancer. They then success-
fully separated and cultured those cells in vitro in patients with 
prostate (9) and bladder cancer (53). Despite these encouraging 
findings, culturing CTCs from patients with GU cancers con-
tinues to be highly technically challenging, and multiple groups 
continue to work to develop improved methods. Ultimately, 
validation of such methods would require reliable culture tech-
niques that could offer clinical utility for a significant portion of 
patients, and confidence that cultured CTCs closely represent the 
underlying molecular phenotype of patients’ disease.
Bladder Cancer
To date, the majority of GU CTC research has been conducted in 
prostate cancer, probably due to its prevalence, the availability of 
large trial cohorts, and the presence of known molecular mark-
ers. All of these are present to a lesser degree in bladder cancer; 
nevertheless, as technologies improve and new treatments (e.g., 
immune checkpoint inhibitors) become available in bladder 
cancer, growing efforts are now invested in liquid biopsy and CTC 
studies in this disease.
Metastatic Disease
Gallagher et al. (54) used CellSearch® to enrich CTCs from 33 
patients with metastatic urothelial cell carcinoma (UCC) and 
detected CTCs in 14/33 (44%) of patients. Median CTC count 
in patients with two or more sites of metastasis was 3.5 vs 0 in 
patients with one metastatic site (p = 0.04). Okegawa et al. (55) 
used CellSearch® to enumerate CTCs in patients with bladder 
cancer. CTCs were detected in 11/20 (55%) patients with meta-
static bladder cancer and in 0/16 patients with non-metastatic 
UCC. Similarly, Naoe and colleagues (56) reported a 57% (8/14) 
detection rate in patients with metastatic disease. While detection 
rates do appear to correlate generally with disease state, the true 
CTC positivity may be impacted by variable EpCAM expression 
that may limit detection in these immunoaffinity-based studies. 
Flaig et al. (57) used the CellSearch® platform and detected ≥1 
CTC in 5/30 of patients with localized and 7/14 of patients with 
metastatic UCC. They also performed FISH using the UroVysion 
(Abbott Molecular, Des Plaines, IL, USA) probe set on 18 unique 
samples collected from the CellSearch® cartridge looking for 
DNA copy number variation (CNV). Nine of these samples were 
collected from patients with detectable CTCs and CNV was 
detected in five samples. None of the nine samples collected from 
patients without CTCs had CNV. All patients with metastatic 
disease and detectable CTCs were dead at <1  year while only 
3/7 patients with metastases but without detectable CTCs were 
deceased at <1 year.
While detection rates do appear to correlate generally with 
disease state, the true CTC positivity may be impacted by 
variable EpCAM expression that may limit detection in these 
immunoaffinity-based studies. Using the Epic Sciences platform 
including immunofluorescent staining and algorithmic scanning, 
Anantharaman et al. (58) examined blood samples from patients 
with metastatic bladder cancer and detected CTCs in 20/25 (80%) 
patients. CK− CTCs were present in 14/25 (56%). Programed 
death-ligand 1 expression was found in both CK+ and CK− cells 
and was associated with decreased overall survival. This study 
illustrates how high content imaging without enrichment may 
identify and characterize additional CTC subpopulations and 
help to guide therapy.
Localized Disease
Gazzaniga et al. (59) collected blood samples from 102 patients 
with T1G3 UCC prior to undergoing transurethral resection 
of bladder tumor. Using the CellSearch® platform, CTCs were 
detected in 20% of patients and their presence was associated 
with time-to-first recurrence, progression-free survival, and the 
development of distant metastasis. In an earlier report from this 
same group on 44 patients with non-muscle-invasive bladder 
cancer, CTCs were detected in 8/44 (18%) of patients, and their 
presence was associated with higher tumor stage and the presence 
of carcinoma in situ (60).
Circulating tumor cell enumeration has also been studied in 
patients undergoing radical cystectomy. Guzzo et al. (61) detected 
CTCs in 9/43 (21%) of patients undergoing radical cystectomy 
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for clinically localized disease. The presence of detectable CTCs 
was not associated with extravesical tumor staging on final 
pathology. Rink et  al. (62) collected blood from 100 patients 
with non-metastatic UCC treated with radical cystectomy. They 
detected CTCs using CellSearch® in 23 patients and reported 
that patients with detectable CTCs had worse recurrence-free 
survival, cancer-specific survival, and overall survival. They also 
stained for HER2 expression in the primary tumor, CTCs, and 
lymph nodes. Of the 22 CTC positive samples evaluated, HER2 
expression was concordant with the primary tumor in 14 (64%) 
cases. For five cases with detectable CTCs and metastatic lymph 
nodes, there was 100% HER2 concordance rate (all stained 
negative).
Alva et al. (63) used the Isoflux™ immunomagnetic enrich-
ment platform to detect CTCs in patients with UCC and compared 
their results to CellSearch®, finding improved CTC identification 
capacity. >10 CTCs was predictive of unfavorable pathology 
(pT1 or greater) from radical cystectomy following neoadjuvant 
chemotherapy (89% PPV) while CTC enumeration <10 was 
predictive of favorable pathology (57% NPV). In addition, they 
were able to detect somatic variants from 4/8 samples using 
next-generation sequencing from spike in samples. Sensitivity 
and specificity in the identification of CTCs using this platform 
will ultimately require further evaluation in the context of larger 
prospective cohorts. However, the detection of single-nucleotide 
variants from enriched cells provide promising genomic results 
and exemplify the potential of expanded studies examining 
single-nucleotide variants from CTCs, primary tumors, and 
metastases to better elucidate clonal disease progression in blad-
der cancer.
An ongoing study in a prospective multicenter clinical trial 
setting is in SWOG S1314, a randomized phase II testing a gene 
panel derived by co-expression extrapolation (COXEN)—as a 
predictive biomarker of response to neoadjuvant chemotherapy 
for localized, muscle-invasive bladder cancer. The primary aim 
of this study is to determine whether the COXEN score derived 
from CTC RNA can predict treatment response to neoadjuvant 
chemotherapy in a manner similar to RNA from bladder tumor 
biopsy. Collectively, these studies in locally advanced and 
metastatic bladder cancer aim to leverage improved recovery 
and amplification techniques to ultimately predict outcome and 
improve therapy selection.
Kidney and Testis
Few studies have been conducted evaluating CTCs in either kid-
ney (64–66) or testis cancer (67), and most have focused on CTC 
enumeration. Nel et al. (64) studied CTCs in metastatic renal cell 
carcinoma patients using multiparameter immunofluorescence 
microscopy and detected subtypes of CTCs consistent with epi-
thelial, mesenchymal, and stem cell-like characteristics. Bluemke 
et al. (65) detected CTCs in 81 (53%) of 154 patients with renal 
cell carcinoma using autoMACS®, an immunomagnetic-based 
platform. They reported that CTC detection was associated 
with positive lymph nodes (p < 0.001), synchronous metastases 
(p = 0.014), and in multivariate Cox regression analysis, CTCs were 
associated with overall survival (RR, 2.3, p = 0.048). An interest-
ing study from Nastaly et al. (67) evaluated CTC enrichment from 
peripheral blood as well as testicular vein blood in patients with 
testicular germ cell tumors (GCTs). CTC detection was associ-
ated with clinical stage, non-seminomatous GCTs, and elevated 
serum levels of α-fetoprotein, human chorionic gonadotropic, 
and lactate dehydrogenase. Furthermore, 14/122 (11.5%) of 
patients had detectable CTCs in peripheral blood, while 12/19 
(63%) of patients had detectable CTCs in testicular vein blood. 
While these preliminary findings are promising, additional larger 
trials are needed in these tumor types to better define the future 
role of CTC analysis in these cancers.
SUMMARY AND FUTURe DiReCTiONS
Whereas the majority of early CTC studies in GU cancer were 
focused on identification and enumeration—an end point with 
clinically important prognostic and predictive value—a growing 
emphasis now is being placed on molecular characterization of 
the tumor cells. As identification, recovery, and characterization 
become more accurate and cost effective, it will be important to 
determine whether the molecular profiles of CTCs provide infor-
mation that can be used as a surrogate for tumor tissue, or whether 
in some cases CTCs provide information exceeding that avail-
able from biopsies (e.g., reflecting new drivers of resistance and 
progression). Gene rearrangements, translocations, differences in 
receptor expression and localization, and splice variations have 
all been successfully assayed in CTCs, and the molecular profiles 
derived from these liquid biopsies ultimately will offer utility in 
directing targeted therapy and selecting patients for appropriate 
clinical trials.
Future CTC studies in GU and other malignancies also will 
need to be integrated with rapidly emerging technologies for iso-
lating and analyzing cell-free circulating tumor DNA (ctDNA), 
which is released from dying cells in primary tumors, metastases, 
and CTCs. Collection, shipping, and isolation of ctDNA are rela-
tively straightforward and qPCR or NGS can be used to monitor 
cancer progression or emergence of new driver mutations (68). 
For example, through the use of ctDNA sequencing technology 
in the setting of CRPC, Lallous et al. (69) identified four single 
AR mutations and five mutation combinations associated with 
CRPC, which could be relevant to prognosis and therapy. In 
non-GU malignancies, ctDNA has demonstrated capacity as an 
accurate biomarker for extent of surgical resection and disease 
relapse (70) as well as a means of detecting therapeutically rel-
evant DNA mutations in both the pre- and postsurgical settings 
(71). Just as CTC fragments were found predictive of prostate 
cancer recurrence, ctDNA offers a useful biomarker of residual 
disease or early disease recurrence and continues to be explored 
clinically with evolving applications (19, 72). An ongoing clinical 
trial, NCT02771769, is examining the utility of ctDNA in men 
with elevated PSA undergoing prostate biopsy to determine if 
copy number instability correlates with prostate cancer diagnosis 
and may reshape the landscape of prostate cancer screening 
(http://clinicaltrials.gov). As with CTCs, ctDNA analysis presents 
important new questions: for example, ctDNA represents the 
genome of dying tumor cells (as well as any other dying non-
tumor cells), so the genomes of treatment-resistant cells may not 
be fully represented or detectable. Moreover, whereas CTCs allow 
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